The triplet therapy of anti-CD38 isatuximab, carfilzomib, and dexamethasone gave a significant improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (R/R MM).
Prof. Philippe Moreau (University Hospital of Nantes, France) presented the interim results of the open-label phase 3 IKEMA study . This study randomised 302 patients with R/R MM who had previously received 1 to 3 lines of therapy to receive either intravenous isatuximab at 10 mg/kg plus carfilzomib and dexamethasone (n=179) or carfilzomib/dexamethasone alone (n=123). Isatuximab was administered weekly for 4 weeks, and then every 2 weeks. Carfilzomib was administered at 20 mg/m2 on the first 2 days and then 56 mg/m2 twice-weekly thereafter for 3 to 4 weeks, followed by twice-weekly dexamethasone at 20 mg. Treatment was given u...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Daratumumab for light-chain amyloidosis Next Article
Initial results from CAR-T cell therapy in MM: KarMMa »
Table of Contents: EHA 2020
Plasma Cell Dyscrasias
Bench-to-Bedside Science from the Presidential Symposium
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.